Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cynata Therapeutics Limited ( (AU:CYP) ) just unveiled an update.
Cynata Therapeutics reported strong clinical and operational progress in the December 2025 quarter, highlighted by completion of final patient visits in its large Phase 3 SCUlpTOR osteoarthritis trial of CYP-004 and completion of patient enrolment in its Phase 2 trial of CYP-001 for newly diagnosed high-risk acute graft versus host disease, with efficacy results from both studies expected in the second quarter of 2026. The company also advanced its Phase 1/2 NEREID kidney transplantation study, where an independent safety board cleared the first cohort treated with CYP-001 with no rejection episodes or safety issues, allowing progression to a second cohort with higher dosing; combined with an estimated available cash position of about $3.8 million and a runway into mid-2026, ongoing regulatory engagement and partnering discussions position Cynata for multiple near-term clinical and strategic catalysts that could influence future approval pathways and commercialisation prospects for its Cymerus™ platform.
The most recent analyst rating on (AU:CYP) stock is a Hold with a A$0.30 price target. To see the full list of analyst forecasts on Cynata Therapeutics Limited stock, see the AU:CYP Stock Forecast page.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company specialising in cell therapeutics based on its Cymerus™ induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (MSC) platform. The company is developing products targeting conditions such as acute graft versus host disease (aGvHD), osteoarthritis of the knee and complications related to kidney transplantation, and is actively engaging with regulators and global partners while strengthening its intellectual property portfolio in the US and Europe.
Average Trading Volume: 289,416
Technical Sentiment Signal: Buy
Current Market Cap: A$74.8M
Find detailed analytics on CYP stock on TipRanks’ Stock Analysis page.